Patents Assigned to The George Washington University a Congressionally Chartered Not-for Profit Corporation
-
Publication number: 20230416739Abstract: This disclosure provides methods of treating obesity, nonalcohol-related fatty liver disease, nonalcoholic steatohepatitis, or hepatocellular cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of at least one siRNA molecule targeting SPTBN1.Type: ApplicationFiled: November 12, 2021Publication date: December 28, 2023Applicant: The George Washington University, A Congressionally Chartered Not-For-Profit CorporationInventors: Lopa MISHRA, Shuyun RAO, Wilma JOGUNOORI, Bibhuti MISHRA, Kazufumi OHSHIRO, Sobia ZAIDI
-
Publication number: 20230405118Abstract: The present disclosure provides signal transducer and activator of transcription (STAT)-activated macrophages, compositions comprising STAT-activated macrophages, methods of making STAT-activated macrophages, and methods of treating diseases, e.g., cancer, by administering a therapeutically effective amount of STAT-activated macrophages.Type: ApplicationFiled: October 29, 2021Publication date: December 21, 2023Applicant: THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATIONInventors: Alejandro VILLAGRA, Satish NOONEPALLE, Maria del Mar Gracia HERNANDEZ
-
Patent number: 11629383Abstract: Methods and kits for diagnosing and/or treating a lower respiratory infection in a subject include obtaining a biological sample from the subject; detecting RNA expression levels of one or more biomarkers in the biological sample and comparing the expression levels of the one or more three biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of the one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.Type: GrantFiled: October 27, 2020Date of Patent: April 18, 2023Assignee: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventors: Timothy A. Mccaffrey, Lakhmir S. Chawla
-
Patent number: 11596715Abstract: This invention relates, e.g., to a Myocyte-based Flow Assist Device (MFAD) for treating a subject in need of increased flow of a biological fluid, such as venous blood or lymph, comprising a sheath which comprises rhythmically contracting myocytes.Type: GrantFiled: July 15, 2019Date of Patent: March 7, 2023Assignee: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Narine Sarvazyan
-
Patent number: 11559559Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: GrantFiled: July 20, 2021Date of Patent: January 24, 2023Assignee: The George Washington University, A Congressionally Chartered Not-For-Profit CorporationInventor: Lakhmir S. Chawla
-
Patent number: 11400185Abstract: The present application relates to biocompatible polymers that exhibit a shape-memory effect, devices made using the materials and methods of producing such materials and devices.Type: GrantFiled: August 25, 2016Date of Patent: August 2, 2022Assignee: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventors: Shida Miao, Wei Zhu, Nathan J. Castro, Lijie G. Zhang
-
Patent number: 11371096Abstract: The invention relates to methods and kits for diagnosing and/or treating appendicitis in a subject, comprising performing one or more assays configured to detect one or more biomarkers on a body fluid sample obtained from the subject to provide one or more assay result(s) and correlating the assay result(s) to the occurrence or nonoccurrence of appendicitis in the subject or likelihood of the future outcome to the subject.Type: GrantFiled: October 22, 2015Date of Patent: June 28, 2022Assignee: The George Washington University A Congressionally Chartered Not-For-Profit CorporationInventors: Lakhmir S. Chawla, Timothy A. McCaffrey
-
Publication number: 20220153709Abstract: The present disclosure provides compounds represented by Formula I: and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof, wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.Type: ApplicationFiled: February 1, 2022Publication date: May 19, 2022Applicants: The George Washington University, A Congressionally Chartered Not-for-Profit Corporation, The Board of Trustees of the University of IllinoisInventors: Alejandro VILLAGRA, Alan P. KOZIKOWSKI, Sida SHEN
-
Patent number: 11160767Abstract: The present disclosure provides methods, pharmaceutical compositions, dosing regimens, and kits comprising 4,4?-trans-dihydroxystilbene (DHS), including methods of treating cancer in a subject and methods of decreasing or reversing resistance to a DNA damaging agent in a subject.Type: GrantFiled: April 11, 2018Date of Patent: November 2, 2021Assignee: The George Washington University, a Congressionally Chartered Not-For-Profit CorporationInventors: Chi-Wei Chen, Yongming Li, Zhiyong Han, Wenge Zhu
-
Patent number: 11131661Abstract: The invention relates to compounds and methods for restoring or preserving cholesterol efflux in a cell infected with Human Immunodeficiency Virus (HIV) by preventing or decreasing an interaction between Negative Regulatory Factor (Nef) protein and Calnexin protein, and methods for screening for such compounds.Type: GrantFiled: April 6, 2020Date of Patent: September 28, 2021Assignee: THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATIONInventors: Alexei Adzhubei, Michael Bukrinsky, Ruth Hunegnaw
-
Patent number: 11096983Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 6.5 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: GrantFiled: April 12, 2019Date of Patent: August 24, 2021Assignee: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Lakhmir S. Chawla
-
Patent number: 11098072Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions, and methods for treating or preventing microbial infection caused by parasites or bacteria, such as Plasmodium falciparum or related Plasmodium parasite species and Mycobacterium tuberculosis or related Mycobacterium bacteria species. The compounds are ?,?-unsaturated analogs of fosmidomycin and can inhibit deoxyxylulose phosphate reductoisomerase (Dxr) in many microbes, such as P. falciparum.Type: GrantFiled: June 27, 2018Date of Patent: August 24, 2021Assignees: The George Washington University, A Congressionally Chartered Not-for-Profit Corporation, Washington University, George Mason University, St. Louis UniversityInventors: Cynthia Dowd, Xu Wang, Robert Carl Brothers, Audrey Ragan Odom John, Rachel Edwards, Marvin Meyers, Stacy Arnett, Robin Couch, Kenneth Heidel
-
Patent number: 11066706Abstract: The invention relates to methods and kits for diagnosing and/or treating appendicitis in a subject, comprising obtaining a biological sample from said subject; detecting RNA expression levels of at least three or more biomarkers in the biological sample and comparing the expression levels of said at least three or more biomarkers to a control sample wherein an increase or decrease in the level of expression of said at least three or more biomarkers as compared to the control sample is indicative of appendicitis.Type: GrantFiled: October 22, 2015Date of Patent: July 20, 2021Assignee: The George Washington University, A Congressionally Chartered Not-For-Profit CorporationInventors: Lakhmir S. Chawla, Timothy A. McCaffrey
-
Publication number: 20210062266Abstract: Methods and kits for diagnosing and/or treating a lower respiratory infection in a subject include obtaining a biological sample from the subject; detecting RNA expression levels of one or more biomarkers in the biological sample and comparing the expression levels of the one or more three biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of the one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.Type: ApplicationFiled: October 27, 2020Publication date: March 4, 2021Applicant: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventors: Timothy A. McCaffrey, Lakhmir S. Chawla
-
Publication number: 20200376073Abstract: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.Type: ApplicationFiled: December 23, 2019Publication date: December 3, 2020Applicant: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Lakhmir S. CHAWLA
-
Publication number: 20200340977Abstract: The invention relates to compounds and methods for restoring or preserving cholesterol efflux in a cell infected with Human Immunodeficiency Virus (HIV) by preventing or decreasing an interaction between Negative Regulatory Factor (Nef) protein and Calnexin protein, and methods for screening for such compounds.Type: ApplicationFiled: April 6, 2020Publication date: October 29, 2020Applicant: THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATIONInventors: Alexei ADZHUBEI, Michael BUKRINSKY, Ruth HUNEGNAW
-
Patent number: 10813941Abstract: A pharmaceutical composition includes a small molecule and a pharmaceutically acceptable excipient. The small molecule interacts with a deoxyxylulose phosphate reductoisomerase (Dxr). A method for treating or preventing a microbial infection in a subject in need thereof includes administering the pharmaceutical composition. A method for inhibiting the growth of a eukaryotic pathogen includes contacting the eukaryotic pathogen with an effective amount of the pharmaceutical composition.Type: GrantFiled: January 23, 2017Date of Patent: October 27, 2020Assignees: The George Washington University, A Congressionally Chartered Not-For-Profit Corporation, Washington University in St. LouisInventors: Cynthia Dowd, Audrey Odom, Rachel Edwards, Robert Brothers
-
Patent number: 10765722Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: GrantFiled: September 19, 2018Date of Patent: September 8, 2020Assignee: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Lakhmir S. Chawla
-
Publication number: 20200237963Abstract: The present application relates to biocompatible polymers that exhibit a shape-memory effect, devices made using the materials and methods of producing such materials and devices.Type: ApplicationFiled: August 25, 2016Publication date: July 30, 2020Applicant: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventors: Shida Miao, Wei Zhu, Nathan J. Castro, Lijie G. Zhang
-
Patent number: 10688223Abstract: Embodiments of the present invention relate to structures and systems having a three-dimensional biomimetic structure with a porous biomimetic three-dimensional scaffold and a coating deposited onto a surface of the porous biomimetic three-dimensional scaffold as well as methods of using and fabricating the like.Type: GrantFiled: July 14, 2017Date of Patent: June 23, 2020Assignee: The George Washington University, a Congressionally Chartered Not-for-Profit CorporationInventors: Haitao Cui, Wei Zhu, Benjamin Holmes, Lijie Grace Zhang